81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)

Background

Significant unmet needs exist for patients with mNSq NSCLC who experience disease progression after treatment with PCT and an ICI. Docetaxel (DOC)-based regimens are commonly used to treat such patients; however, data on the characteristics of and outcomes for those receiving these therapies in the real world are lacking. The objective of this study was to provide a benchmark for survival with present standard-of-care therapies by conducting a retrospective cohort study of real-world patients treated with DOC or DOC plus ramucirumab (DOC+RAM) in the US.

Methods

The study utilized data from US patients included in the ConcertAI Patient 360 NSCLC database who initiated first-line treatment between 01-Jul-2016 and 31-Dec-2020. Patients who had mNSq NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received DOC or DOC+RAM following disease progression after PCT and an ICI (in combination or separately) were eligible. Patients’ demographics and clinical characteristics as well as outcomes (real-world overall survival [OS], progression-free survival [PFS], time to treatment discontinuation [TTD], and time to next treatment [TTNT]) were analyzed.

Results

For patients receiving DOC (N=41; mean age: 65 years) or DOC+RAM (N=87; mean age: 64 years), median OS was 6.0 months (95% confidence interval [CI]: 4.8, 11.6) and 5.9 months (95% CI: 4.2, 11.6), respectively. Median PFS was 2.9 months (95% CI: 1.9, 4.6) for DOC and 2.7 months (95% CI: 2.3, 4.6) for DOC+RAM. Median TTD and TTNT were 2.1 months (95% CI: 1.4, 3.4) and 7.4 months (95% CI: 5.7, not estimable [NE]) for DOC and 1.5 months (95% CI: 1.4, 2.1) and 15.2 months (95% CI: 12.3, NE) for DOC+RAM, respectively. Estimates for TTNT should be considered with caution, given that a large number of patients were censored because of death or end of follow-up.

Conclusions

This study highlights the poor prognosis for real-world mNSq NSCLC patients who experience disease progression after PCT and ICI. The results can be used to help evaluate novel therapies in this population.

Editorial acknowledgement

Hriticka Choudhurry and Pranshu Roy from Sanofi provided medical writing support.

Legal entity responsible for the study

Sanofi.

Funding

Sanofi.

Disclosure

M.A. Bittoni: Financial Interests, Institutional, Speaker, Consultant, Advisor, consultancy services: Sanofi. S. Keeping, J.E. Park, A.T.H. Nguyen, K. Toor: Financial Interests, Institutional, Full or part-time Employment: PRECISIONheor; Professional service fees for conducting this research: Sanofi. D.P. Carbone: Financial Interests, Institutional, Speaker, Consultant, Advisor, consultancy services Sanofi. N. Petruski-Ivleva, A.K. Vadanahalli Shankar, G. Konidaris: Financial Interests, Institutional, Full or part-time Employment: Sanofi; Financial Interests, Institutional, Stocks/Shares: Sanofi.